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It was in 1964 that V. G. Allfrey and colleagues ﬁrst reported
the isolation of acetylated histones and speculated—well
ahead of their time—about their possible role in RNA syn-
thesis [1]. About ten years later, the nucleosome was deﬁned
as the basic unit of chromatin [2] and soon thereafter DNA-
seI hypersensitivity analysis of isolated HeLa cells nuclei
demonstrated that histone acetylation impacts on chromatin
structure [3].
Since then, the importance of acetylation for the regula-
tion of chromatin and gene activity has been demonstrated
by numerous studies and this posttranslational modiﬁcation
is now rivaling phosphorylation in its importance. The ﬁeld
beneﬁtted enormously from the early identiﬁcation of mole-
cules, such as Trichostatin A, which inhibit the enzymes
removing acetyl groups—histone deacetylases (HDACs)—
and thus lead to hyperacetylation of histones and chromatin
[4]. These HDAC inhibitors (HDACis) turned out to have
very interesting biological eﬀects, such as induction of diﬀer-
entiation in cellular model systems. In addition, it had been
realized that HDACis show antiproliferative potential when
applied to cultures of transformed cells [5] and this sparked
an enormous interest in their potential use for therapeutic
purposes. A variety of substances, coming from natural or
syntheticsources,havebeentestedincancermodels,andalso
in other pathologies, such as neurodegeneration, autoimmu-
nity, or inﬂammation: in many cases target they were found
to be beneﬁcial. These inhibitors usually all or most of the
HDACs—there are eleven of them—and therefore it is not
clear yet which HDAC(s) are implicated in which pathology.
The last ten years have witnessed a wealth of clinical trials,
primarily in cancer, and also more recently in other settings,
and today two inhibitors—SAHA and romidepsin—have
beenapprovedforclinicaltreatmentofcutaneousTcelllym-
phoma. In parallel to this, genetic analysis of HDACs has
progressed, in particular in the mouse, where all HDACs
have now been ablated. This analysis revealed that some
HDACs, such as HDAC1 or 3, are essential genes [6, 7],
while others are dispensable for development, but show spe-
ciﬁc phenotypes when ablated, for example, organism-wide
increasedtubulinacetylationinthecaseofHDAC6knockout
mice [8]. In addition, conditional alleles of these and other
HDACs have been generated allowing to test their function
in speciﬁc organs or in combinations, by using appropriate
Cre-expressingmicelines.Thesestudiesidentiﬁedimportant
roles for HDACs, for example, in the nervous system, in the
heart, or in lymphocytes [9–11].
This special issue deals with “protein acetylation and the
physiological role of HDACs.” As should be evident from the
important short introduction above, this is an exciting topic
whichhasimplicationsforbasicresearchandademonstrated
increasing medical relevance.
Several reviews address the general role or regulation of
HDACs (T. Hayakawa and J. I. Nakayama; C. Segre and S. M.
Chiocca; A. Peserico and C. Simone). A number of reviews
cover our recent understanding of the role of HDACs in
cancer and various models are discussed, such as—among
others—leukemia (C. Biagi et al.; L. Bagella and M. Fed-
erico), pancreatic cancer (A. Ouaissi et al.; C. Bevan and D.
Lavery), breast cancer (A. Linares et al.), or the link between
autophagy, apoptosis, and HDAC inhibition in cancer cells
(H. Rikiishi). Also, several reviews address important aspects
of HDAC function on nonhistone proteins (e.g., on inter-
feron regulatory factor, A. Masumi) and in particular their
role in the cytoplasm (S. Khochbin et al.; W.-M. Yang and2 Journal of Biomedicine and Biotechnology
Y.-L. Yao; C. Creppe and M. Buschbeck). The importance of
HDACs on cardiac development and function or in hypoxia
is also addressed (H. Kook and H. J. Kee; N. Sang and S.
Chen) and a number of additional topics are touched upon
by dedicated reviews or a few primary data papers.
In summary, this special issue gives an excellent overview
of the current status of research on HDACs and should be a
valuablesourceofreferencematerialforstudentsorresearch-
ers.
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